CN1480172A - Preparation of compound puerarin - Google Patents
Preparation of compound puerarin Download PDFInfo
- Publication number
- CN1480172A CN1480172A CNA021394172A CN02139417A CN1480172A CN 1480172 A CN1480172 A CN 1480172A CN A021394172 A CNA021394172 A CN A021394172A CN 02139417 A CN02139417 A CN 02139417A CN 1480172 A CN1480172 A CN 1480172A
- Authority
- CN
- China
- Prior art keywords
- puerarin
- preparation
- semen ginkgo
- described compound
- ginkalide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 title claims abstract description 46
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 28
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 21
- 241000218628 Ginkgo Species 0.000 claims abstract description 20
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 20
- 210000000582 semen Anatomy 0.000 claims description 18
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 claims description 10
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 claims description 6
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 claims description 6
- 150000007529 inorganic bases Chemical class 0.000 claims description 6
- AMOGMTLMADGEOQ-FNZROXQESA-N Ginkgolide C Chemical compound O([C@H]1O2)C(=O)[C@H](O)C31[C@]14[C@@H](O)[C@@H]5OC(=O)[C@@H](C)[C@]5(O)[C@@]12C(=O)O[C@@H]4[C@@H](O)[C@H]3C(C)(C)C AMOGMTLMADGEOQ-FNZROXQESA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- AMOGMTLMADGEOQ-DPFZUGDXSA-N ginkgolide C Natural products O=C1[C@@H](C)[C@]2(O)[C@H]([C@H](O)[C@@]34[C@H]5[C@H](O)[C@@H](C(C)(C)C)[C@]63[C@H](O)C(=O)O[C@H]6O[C@@]24C(=O)O5)O1 AMOGMTLMADGEOQ-DPFZUGDXSA-N 0.000 claims description 4
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- -1 HP- Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 230000000916 dilatatory effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 238000004108 freeze drying Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine "Compound kakonein" for dilating blood vessel contains kakonein and ginkgo extract in weight ratio of 10:((0.1-10). Its advantages are high curative effect and short course of treatment.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation for the treatment of coronary heart disease and cerebral embolism, be specifically related to a kind of compound puerarin preparation.
Background technology
Puerarin preparation is a kind of blood vessel dilating medicine, and Semen Ginkgo (Ginkgo biloba L.) to be glacial epoch survival hole on earth lose plant, have " living fossil " title.China is the cradle of Semen Ginkgo, and resource accounts for about 70% of world's total amount.At the beginning of the sixties, German Dr Willar Schwabe (Weimar. Shi Wabai) obtains Semen Ginkgo extrac (EGb761) from Folium Ginkgo first, is used for the treatment of cardiovascular and cerebrovascular disease and nervous system disease and has significant curative effect, and do not have significant side effects; Bilobalide has significant anti-platelet activating factor important physiologically actives such as (PAF).The puerarin injection of present clinical use is colourless or faint yellow clear liquid according to the preparation of the WS-257 of Ministry of Health of the People's Republic of China (X-207)-92 ministry standard regulation.The patent No. is 99100213.X, name is called puerarin freeze-drying injectable powder and preparation method thereof, the puerarin freeze-drying injectable powder that proposes contains the alkaline matter of puerarin and pharmacology permission, preparation method is that puerarin is allocated by the alkaline matter that allows under the different pharmacology conditions, make clear liquor, carry out lyophilization by freeze-dry process then, make the puerarin freeze-drying injectable powder.Prior art is owing to only use single puerarin, and treatment coronary heart disease and cerebral embolism effect are not good enough.
Summary of the invention
The present invention is for overcoming the deficiency of prior art, propose a kind of aspect blood vessel dilating the higher compound puerarin preparation of drug effect.
The scheme of technical solution problem of the present invention is:
Compound puerarin preparation contains puerarin and Semen Ginkgo extrac, puerarin: the weight ratio of Semen Ginkgo extrac is 10: 0.1-10.
Semen Ginkgo extrac in the preparation can be a mixture, be Semen Ginkgo extrac (EGb), also can be a kind of monomer component in the Semen Ginkgo, as ginkalide A (Ginkgolide A), ginkalide B (Ginkgolide B), ginkalide C (Ginkgolide C) or bilobalide (Bilobalide).
Also contain the adjuvant that helps into dissolving and molding in the preparation.
Hydrotropy adjuvant used in the present invention can be the mixture of polyvinylpyrrolidone, HP-, propylene glycol, inorganic base or basic amino acid or a kind of inorganic base and a kind of basic amino acid, and wherein inorganic base is preferably sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate; Basic amino acid is preferably: lysine, arginine, histidine.
Lyophilizing skeleton of the present invention is preferably mannitol, lactose.
Puerarin compound preparation of the present invention can be made into the various dosage forms that allow on the pharmaceutics in use.
The present invention compared with prior art, owing in puerarin preparation, added Semen Ginkgo extrac, two kinds of medicines are mutually promoted, not only significantly improved the curative effect of this compound preparation aspect the heart, cerebrovascular, but also can reduce puerarin unit administration amount, shorten treatment cycle.
The specific embodiment:
The present invention is further described below in conjunction with embodiment.
Embodiment 1:
Compound puerarin preparation contains 10g puerarin, 0.1g ginkalide A (Ginkgolide A), 0.5g mannitol and 5g sodium bicarbonate.Carry out lyophilization by freeze-dry process during use, make specification and be every bottle and contain the injectable powder that puerarin and ginkalide A (Ginkgolide A) are respectively 0.1g, 0.001g.
Embodiment 2:
Compound puerarin preparation contains 5g puerarin, 2.5g Semen Ginkgo extrac (EGb), 0.5g mannitol and 10g polyvinylpyrrolidone.Carry out lyophilization by freeze-dry process during use, make specification and be every bottle and contain the injectable powder that puerarin and Semen Ginkgo extrac (EGb) are respectively 0.1g, 0.05g.
Embodiment 3:
Compound puerarin preparation contains 5g puerarin, 0.2g ginkalide B (Ginkgolide B), 0.5g mannitol and 3g HP-.Carry out lyophilization by freeze-dry process during use, make specification and be every bottle and contain the injection that puerarin and ginkalide B (Ginkgolide B) are respectively 0.1g, 0.004g.
Embodiment 4:
Compound puerarin preparation contains 5g puerarin, 1g ginkalide C (Ginkgolide C), 0.5g mannitol and 10g sodium bicarbonate.Carry out lyophilization by freeze-dry process during use, make specification and be every bottle and contain the injection that puerarin and ginkalide C (Ginkgolide C) are respectively 0.1g, 0.02g.
Embodiment 5:
Compound puerarin preparation contains 10g puerarin, 1g ginkalide A (Ginkgolide A), 0.5g mannitol and 10g propylene glycol.Carry out lyophilization by freeze-dry process during use, make specification and be every bottle and contain the injectable powder that puerarin and ginkalide A (Ginkgolide A) are respectively 0.1g, 0.001g.
Embodiment 6:
Compound puerarin preparation contains 5g puerarin, 5g Semen Ginkgo extrac (EGb).Can be made into specification during use and be every and contain the tablet that puerarin and Semen Ginkgo extrac (EGb) are respectively 0.1g, 0.1g.
Claims (7)
1 one kinds of compound puerarin preparations is characterized in that: preparation contains puerarin and Semen Ginkgo extrac, and puerarin and Semen Ginkgo extrac are by weight 10: 0.1-10.
2 according to claims 1 described compound puerarin preparation, it is characterized in that Semen Ginkgo extrac can be a mixture, be Semen Ginkgo extrac (EGb), also can be a kind of monomer component in the Semen Ginkgo, as ginkalide A (Ginkgolide A), ginkalide B (Ginkgolide B), ginkalide C (Ginkgolide C) or bilobalide (Bilobalide).
3 according to claims 1 described compound puerarin preparation, it is characterized in that also comprising the cosolvent of medicinal allowance.
4 according to claims 3 described compound puerarin preparations, the cosolvent that it is characterized in that medicinal allowance is the mixture of polyvinylpyrrolidone, HP-, propylene glycol, inorganic base or basic amino acid or a kind of inorganic base and a kind of basic amino acid, and wherein inorganic base is preferably sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate; Basic amino acid is preferably: lysine, arginine, histidine.
5 according to claims 1 described compound puerarin preparation, it is characterized in that also comprising the excipient of medicinal allowance.
6 according to claims 5 described compound puerarin preparations, it is characterized in that used excipient is mannitol or lactose.
7 according to claims 1 described compound puerarin preparation, it is characterized in that Clicking here and can make the various dosage forms that allow on the pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021394172A CN100427109C (en) | 2002-09-02 | 2002-09-02 | Preparation of compound puerarin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021394172A CN100427109C (en) | 2002-09-02 | 2002-09-02 | Preparation of compound puerarin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1480172A true CN1480172A (en) | 2004-03-10 |
| CN100427109C CN100427109C (en) | 2008-10-22 |
Family
ID=34147437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021394172A Expired - Lifetime CN100427109C (en) | 2002-09-02 | 2002-09-02 | Preparation of compound puerarin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100427109C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773529A (en) * | 2010-03-19 | 2010-07-14 | 庄洪波 | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation thereof |
| CN105287499A (en) * | 2015-10-09 | 2016-02-03 | 成都普瑞法科技开发有限公司 | Natural pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular diseases and application of pharmaceutical composition |
| CN115624148A (en) * | 2022-10-25 | 2023-01-20 | 徐州工程学院 | Sea sedge roll and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044861C (en) * | 1993-08-21 | 1999-09-01 | 陕西省中医药研究院 | Injection for treatment of infarction |
| CN1074673C (en) * | 1998-07-17 | 2001-11-14 | 山东绿叶制药股份有限公司 | Traditional Chinese medicine compositions contg. pueraria root extract |
| CN1188124C (en) * | 2000-03-24 | 2005-02-09 | 中国科学院上海药物研究所 | Process for preparing ginkgolide injection |
-
2002
- 2002-09-02 CN CNB021394172A patent/CN100427109C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773529A (en) * | 2010-03-19 | 2010-07-14 | 庄洪波 | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation thereof |
| CN101773529B (en) * | 2010-03-19 | 2012-08-08 | 庄洪波 | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation thereof |
| CN105287499A (en) * | 2015-10-09 | 2016-02-03 | 成都普瑞法科技开发有限公司 | Natural pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular diseases and application of pharmaceutical composition |
| CN115624148A (en) * | 2022-10-25 | 2023-01-20 | 徐州工程学院 | Sea sedge roll and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100427109C (en) | 2008-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1112198C (en) | Thrombolytic medicine and its preparation and use | |
| CN1173707C (en) | Medicinal composition containing baicalin and caffoeoylchinic acid | |
| CN1977878A (en) | Chinese medicine composition and its use | |
| CN100427109C (en) | Preparation of compound puerarin | |
| CN113368224B (en) | Traditional Chinese medicine composition buccal tablet based on hirudin and preparation method thereof | |
| CN101036708A (en) | Medicine composition for treatment of cardio-cerebralvascular disease | |
| CN1215847C (en) | Control released osmotic pump prepn containing ligustrazine phosphate and its prepn process | |
| CN1762341A (en) | Salvianolic acid compound for treating cardiovascular and cerebrovascular disease and liver disease, and application thereof | |
| CN101628003A (en) | Extract of ginkgo biloba leaves and dipyridamole composite and preparation method and application thereof | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1177603C (en) | Gingko leaf slow-releasing table and preparation process thereof | |
| CN1768753A (en) | Medicinal composition containing bilobalide B and its preparation process and usage | |
| CN1762362A (en) | Medicinal composition with red sage root component for treating cardiovascular and cerebrovascular disease and its application | |
| CN1552723A (en) | Liaodong oak leaf saponin and its medicinal composition | |
| CN1965919A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1176656C (en) | Freeze-drying composition for injection | |
| CN1395933A (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1785988A (en) | Saflor yellow pigment rich in saflor yellow pigment B, its preparation method and use | |
| CN1616069A (en) | Ginkgo medicine composition, its preparing method and its use | |
| CN1596954A (en) | Red ginseng and ophiopogon root preparation and its making method | |
| CN1562345A (en) | Drug combination including activator for metabolism of brain and free radical scavenger | |
| CN1593574A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| JPH0477426A (en) | Relaxant for vascular smooth muscle | |
| CN1915237A (en) | Medicinal composition, preparation method and quality control method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A compound puerarin preparation Effective date of registration: 20160104 Granted publication date: 20081022 Pledgee: Ankang city credit financing Company limited by guarantee Pledgor: ANKANG PHARMACEUTICAL INSTITUTE OF PEKING University Registration number: 2015610000022 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 725000 No. 6 Pioneering East Road, Ankang High-tech Industrial Development Zone, Shaanxi Province Patentee after: Ankang Innovation Institute of Chinese Pharmaceutical Research Co.,Ltd. Address before: 725000 No. 2 Xing'an East Road, Ankang City, Shaanxi Province Patentee before: ANKANG PHARMACEUTICAL INSTITUTE OF PEKING University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190212 Address after: 725000 No. 6 Pioneering East Road, Ankang High-tech Industrial Development Zone, Shaanxi Province Patentee after: ANKANG BEIYIDA PHARMACEUTICAL CO.,LTD. Address before: 725000 No. 6 Pioneering East Road, Ankang High-tech Industrial Development Zone, Shaanxi Province Patentee before: Ankang Innovation Institute of Chinese Pharmaceutical Research Co.,Ltd. |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210111 Granted publication date: 20081022 Pledgee: Ankang city credit financing Company limited by guarantee Pledgor: ANKANG PHARMACEUTICAL INSTITUTE OF PEKING University Registration number: 2015610000022 |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20081022 |